Abstract
Report description
The Co-promotion and Co-marketing Agreements in Pharma, Biotech and
Diagnostics report provides comprehensive understanding and unprecedented
access to the co-promotion and co-marketing partnering agreements entered into
by the worlds leading biopharma companies.
This report provides details of the
latest co-promotion and co-marketing agreements announced in the
pharmaceutical, biotechnology and diagnostic sectors. Fully revised and
updated, the report provides details of co-promotion and co-marketing
agreements from 2003 to end 2008. The report provides a detailed understand
and analysis of how and why companies enter co-promotion and co-marketing
deals. The majority of deals are multicomponent whereby the licensor retains
either a right or option to co-promote/market the resultant product of the
research collaboration. There are also numerous pure co-promotion/marketing
deals whereby the products originator takes on a co-promotion/marketing
partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner' s negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not. This report contains
over 600 links to online copies of actual co-promotion and co-marketing
contract documents as submitted to the Securities Exchange Commission by
biopharma companies and their partners. Contract documents provide the answers
to numerous questions about a prospective partner' s flexibility on a wide
range of important issues, many of which will have a significant impact on
each party' s ability to derive value from the deal. The initial chapters of
this report provide an orientation of co-promotion and co-marketing dealmaking
and business activities. Chapter 1 provides an introduction to the report,
whilst Chapter 2 provides an analysis of the trends in co-promotion and
co-marketing as well as a discussion on the merits of each type of deal.
Chapters 3 and 4 provide an overview of the structure of co-promotion and
co-marketing deals, respectively. Each Chapter includes numerous case studies
to enable understanding of both pure co-promotion/marketing deals and
multicomponent deals where co-promotion/marketing forms a part. Chapters 5 and
6 provide a review of the leading co-promotion and co-marketing deals since
2000, respectively. Deals are listed by headline value, signed by bigpharma,
most active bigpharma, and most active of all biopharma companies. Where the
deal has an agreement contract published at the SEC a link provides online
access to the contract. Chapter 7 provides a comprehensive listing of the top
50 bigpharma companies with a brief summary followed by a comprehensive
listing of co-promotion and co-marketing contract documents available in the
public domain. Each deal title links via Weblink to an online version of the
actual contract document, providing easy access to each contract document on
demand. Chapters 8 and 9 provide a comprehensive listing of all co-promotion
and co-marketing agreement contracts available in the public domain,
respectively. Each Chapter is organized by A-Z, stage of development at
signing, and therapeutic area. Each deal title links via Weblink to an online
version of the actual contract document, providing easy access to each
contract document on demand.
Key benefits
Co-promotion and Co-marketing Agreements in Pharma, Biotech and
Diagnostics provides the reader with the following key benefits:
- In-depth understanding of co-promotion and co-marketing deal trends since
2000
- Analysis of the structure of co-promotion and co-marketing agreements with
numerous real life case studies
- Comprehensive access to over 600 actual co-promotion and co-marketing
contracts entered into by the world' s biopharma companies*
- Detailed access to actual co-promotion and co-marketing contracts enter
into by the leading fifty bigpharma companies*
- Insight into the terms included in a co-promotion and co-marketing
agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities
Exchange Commission.
Report scope
Co-promotion and Co-marketing Agreements in Pharma, Biotech and
Diagnostics is intended to provide the reader with an in-depth
understanding of the co-promotion and co-marketing trends and structure of
deals entered into by leading biopharma companies worldwide.
Co-promotion and Co-marketing Agreements in Pharma, Biotech and
Diagnostics includes:
- Trends in co-promotion and co-marketing dealmaking in the biopharma
industry since 2000
- Analysis of co-promotion and co-marketing deal structure
- Case studies of real-life co-promotion and co-marketing deals
- Access to over 600 co-promotion and co-marketing contract documents
- The leading co-promotion and co-marketing deals by value since 2000
- Most active co-promotion and co-marketing dealmakers since 2000
- The leading co-promotion and co-marketing partnering resources
In Co-promotion and Co-marketing Agreements in Pharma, Biotech and
Diagnostics, the available contracts are listed by:
- A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
Each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
The Co-promotion and Co-marketing Agreements in Pharma, Biotech and
Diagnostics report provides comprehensive access to available contract
documents for over 600 co-promotion and co-marketing deals. Analyzing actual
contract agreements allows assessment of the following:
- What are the precise co-promotion and co-marketing rights granted or
optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Number of pages: The report is comprised of 365 pages.
| 
View Cart
